CYTOKINETICS, INCORPORATED Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
CYTOKINETICS, INCORPORATED (CYTK) reported Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit of $11.10 per share for the 12-month period ending 2013-12-31, per its 10-K filed 2016-03-03.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit · last filed 2016-03-03
- CYTOKINETICS, INCORPORATED share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2013 was $11.10.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2011 was $7.20, a 260.00% increase from fiscal 2010.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2010 was $2.00, a 59.60% decline from fiscal 2009.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2009 was $4.95, a 46.88% increase from fiscal 2008.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 12 month | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 12 month as first filed |
|---|---|---|
| 2013-12-31 | $11.10 10-K · filed 2016-03-03 | |
| 2011-12-31 | $7.20 10-K · filed 2014-03-07 | $1.20 10-K · filed 2012-03-13 |
| 2010-12-31 | $2.00 10-K · filed 2013-03-15 | |
| 2009-12-31 | $4.95 10-K · filed 2013-03-15 | |
| 2008-12-31 | $3.37 10-K · filed 2013-03-15 | |
| 2007-12-31 | $7.10 10-K · filed 2013-03-15 | |
| 2006-12-31 | $7.10 10-K · filed 2013-03-15 | |
| 2005-12-31 | $7.10 10-K · filed 2013-03-15 | |
| 2004-12-31 | $6.50 10-K · filed 2013-03-15 | |
| 2003-12-31 | $1.20 10-K · filed 2013-03-15 | |
| 2002-12-31 | $1.20 10-K · filed 2013-03-15 | |
| 2001-12-31 | $1.20 10-K · filed 2013-03-15 | |
| 2000-12-31 | $0.58 10-K · filed 2013-03-15 | |
| 1999-12-31 | $0.58 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |